Equities research analysts expect Bellerophon Therapeutics Inc (NASDAQ:BLPH) to post earnings per share (EPS) of ($0.08) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Bellerophon Therapeutics’ earnings. The lowest EPS estimate is ($0.09) and the highest is ($0.06). Bellerophon Therapeutics reported earnings per share of $0.18 in the same quarter last year, which suggests a negative year over year growth rate of 144.4%. The firm is expected to announce its next earnings results on Wednesday, November 6th.

On average, analysts expect that Bellerophon Therapeutics will report full-year earnings of ($0.23) per share for the current financial year, with EPS estimates ranging from ($0.26) to ($0.20). For the next year, analysts expect that the firm will post earnings of ($0.31) per share, with EPS estimates ranging from ($0.44) to ($0.17). Zacks’ EPS averages are a mean average based on a survey of research firms that cover Bellerophon Therapeutics.

Bellerophon Therapeutics (NASDAQ:BLPH) last issued its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.01.

Several equities analysts have recently commented on the stock. Maxim Group reaffirmed a “buy” rating and set a $2.00 price objective on shares of Bellerophon Therapeutics in a research note on Friday, August 9th. Zacks Investment Research raised shares of Bellerophon Therapeutics from a “hold” rating to a “buy” rating and set a $0.75 price objective for the company in a research note on Wednesday, May 15th. Finally, ValuEngine raised shares of Bellerophon Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, August 1st.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC increased its position in shares of Bellerophon Therapeutics by 13.1% during the fourth quarter. Geode Capital Management LLC now owns 232,890 shares of the biotechnology company’s stock valued at $186,000 after buying an additional 27,027 shares during the period. Arch Venture Corp purchased a new position in shares of Bellerophon Therapeutics during the first quarter valued at about $631,000. Vanguard Group Inc. increased its position in shares of Bellerophon Therapeutics by 15.9% during the second quarter. Vanguard Group Inc. now owns 1,152,175 shares of the biotechnology company’s stock valued at $690,000 after buying an additional 158,000 shares during the period. Renaissance Technologies LLC increased its position in shares of Bellerophon Therapeutics by 8.9% during the second quarter. Renaissance Technologies LLC now owns 1,434,538 shares of the biotechnology company’s stock valued at $860,000 after buying an additional 116,862 shares during the period. Finally, LPL Financial LLC increased its position in shares of Bellerophon Therapeutics by 22.1% during the second quarter. LPL Financial LLC now owns 130,800 shares of the biotechnology company’s stock valued at $78,000 after buying an additional 23,650 shares during the period. Institutional investors own 53.36% of the company’s stock.

Shares of NASDAQ:BLPH traded up $0.03 during midday trading on Friday, hitting $0.58. 202,300 shares of the stock traded hands, compared to its average volume of 257,139. The stock has a market capitalization of $39.63 million, a PE ratio of -1.71 and a beta of -0.02. The business’s 50 day moving average is $0.62 and its two-hundred day moving average is $0.64. The company has a quick ratio of 2.64, a current ratio of 2.64 and a debt-to-equity ratio of 0.15. Bellerophon Therapeutics has a one year low of $0.49 and a one year high of $1.28.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company engages in two programs including INOpulse and BCM.

Further Reading: How Investors Use a Balance Sheet

Get a free copy of the Zacks research report on Bellerophon Therapeutics (BLPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bellerophon Therapeutics (NASDAQ:BLPH)

Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.